title: Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates.
abstract: 1. Cell-surface expression of CD40 in B-cell malignancies and multiple solid tumors has raised interest in its potential use as a target for antibody-based cancer therapy. SGN-40, a humanized monoclonal anti-CD40 antibody, mediates antibody-dependent cytotoxicity and inhibits B-cell tumor growth in vitro, properties of interest for the treatment of cancers, and is currently in Phase I clinical trials for B-cell malignancies. In this study, we determined in vivo activity and pharmacokinetics properties of SGN-40. 2. Effect of SGN-40 in xenograft model of CD40-expressing B-cell lymphoma in severe-combined immune deficiency mice and its in vivo pharmacokinetics properties in normal mice, rats and cynomolgus monkeys were studied. 3. Treatment with SGN-40 significantly increased the survival of mice xenografted with human B-cell lymphoma cell line. SGN-40 exhibited nearly 100% bioavailability in mice and it cleared faster when given at a low dose. In monkeys, clearance of SGN-40 was also much faster at low dose, suggesting nonlinear pharmacokinetics in these species. In rats, however, SGN-40 clearance at all tested doses was similar, suggesting that pharmacokinetics were linear in this dose range in rats. Administration of SGN-40 to monkeys also produced marked, dose-dependent, and persistent depletion of peripheral CD20(+) B lymphocytes. 4. Data presented in this report suggest that SGN-40 is active in in vivo, and based upon interspecies scaling, SGN-40 clearance in humans is predicted to be similar to observed SGN-40 clearance in monkeys. These data suggest that SGN-40 has appropriate pharmacokinetic properties that support its clinical use.
authors.affiliation: Product Portfolio Management, Genentech Inc., South San Francisco, CA, USA.
authors.forename: Sean K
authors.initials: SK
authors.lastname: Kelley
authors.forename: Thomas
authors.initials: T
authors.lastname: Gelzleichter
authors.forename: Dong
authors.initials: D
authors.lastname: Xie
authors.forename: Wyne P
authors.initials: WP
authors.lastname: Lee
authors.forename: Walter C
authors.initials: WC
authors.lastname: Darbonne
authors.forename: Ferhan
authors.initials: F
authors.lastname: Qureshi
authors.forename: Kim
authors.initials: K
authors.lastname: Kissler
authors.forename: Ezogelin
authors.initials: E
authors.lastname: Oflazoglu
authors.forename: Iqbal S
authors.initials: IS
authors.lastname: Grewal
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000493:pharmacokinetics / Q000494:pharmacology*; D019013:CD40 Antigens / Q000276:immunology*; D004797:Enzyme-Linked Immunosorbent Assay; D005434:Flow Cytometry; D008252:Macaca fascicularis; D008297:Male; D051379:Mice; D016513:Mice, SCID; D013045:Species Specificity
chemical_list: D000911:Antibodies, Monoclonal; D019013:CD40 Antigens